|
68Ga-Dotatate Clinical Trials
4 actively recruiting trials across 2 locations
Also known as: CT scan, PET scan, blood collection
Pipeline
Early 1: 1Phase 1: 1Phase 2: 1Phase 1/2: 1
Top Sponsors
- National Cancer Institute (NCI)2
- Peking Union Medical College Hospital1
- Akiva Mintz1
Indications
- Cancer4
- Gastrointestinal Neuroendocrine Tumors2
- Somatostatin Receptor Positive2
- Pheochromocytoma2
- Healthy (Controls)1
Bethesda, Maryland2 trials
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
National Institutes of Health Clinical Center
Phase 1/2
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
National Institutes of Health Clinical Center
Phase 1
Other1 trial
Englewood, New Jersey1 trial
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake
Nuclear Imaging Institute
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.